Core Viewpoint - The Swiss biopharmaceutical company's shares experienced a significant increase in after-hours trading following the FDA's approval of its Optune Pax product [1] Company Summary - The company is a Swiss biopharmaceutical firm that has recently received FDA approval for its product, Optune Pax [1] - The approval has positively impacted the company's stock performance, leading to a surge in share prices during after-hours trading [1] Industry Summary - The FDA's approval of new biopharmaceutical products is a critical factor influencing stock prices and investor sentiment within the biopharmaceutical industry [1] - The successful launch of innovative products like Optune Pax can enhance a company's market position and drive future growth in the biopharmaceutical sector [1]